PIK3CA and ovarian cancer: Langdon et al. used two PI3K/mTOR inhibitors, gedatolisib and PF-04691502, to study six human patient-derived ovarian cancer xenograft models and found that both compounds exhibit antitumour activity on all the experimental substances, and the initial tumour volume inhibitory effect seems to be the strongest.